Title of the cohort
The Cardiovascular Risk Factors, Aging, and Dementia Study
Acronym for cohort
CAIDE
Name of Principal Investigator
| Title | MD, PhD, Associate Professor |
| First name | Miia |
| Last name | Kivipelto |
Address of institution where award is held
| Institution | Aging Research Center, Karolinska Institutet |
| Street Address | |
| City | Stockholm |
| Postcode | 113 30 |
Country
- Sweden
Website
http://www.uef.fi/caide/home
Contact email
Funding source
1) Swedish Research Council (VR)
2) Academy of Finland
3) Alzheimer Association
4) Novo-Nordisk
1. The cohort includes, or expects to include, incidence of the following conditions
- Alzheimer’s disease and other dementias
- Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible
- Already possible
2a. Stated aim of the cohort
To investiagte cardiovascular and lifestyle related risk factors for cognitive impairment and dementia
2b. Features distinguishing this cohort from other population cohorts
Data available already from midlife and follow-up time over 30 years
3a. i) Number of publications that involve use of cohort to date
50
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
| Age in years from: | 65 |
| To (‘until death’ if applicable): | 79 |
4b. Study criteria: inclusion criteria
Differential diagnoses for dementing disorders including brain MRI, CSF, ECG, blood tests and more detailed neuropsyvhological evaluation
4c. Study criteria: exclusion criteria
No
5. Size of the cohort (i.e. number of participants enrolled)
- 1,000 – 5,000 participants
6a. Measures used to characterise participants
Cognitive tests, health and life-style questionnary, physcial examination, and blood samples
6b. Additional measures for participants with a clinical disorder
Mild cognitive impairment, dementia, Alzheimer’s disease
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
Cognitive impairment, mild cognitive impairment, dementia and Alzheimer’s disease
7. Study design
- Prospective cohort
8. Cases matched by
- Age
- Sex
- Other health assessment (specify) / N/A
- We have used a reprentative population based sample. In some sub-studies, i.e. MRI we have used case-control design
9a. Does the study include a specialised subset of control participants
- No
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date
01-01-1998
10a. ii) Data collection end date
10a iii) Data collection for this study is
- Data analysis ongoing
10b. Plans to continue the cohort study beyond the current projected end date
- Yes – intend to apply for funding
11. Data collected
- Only through the study
- Through links to medical records
12. System in place to enable re-contact with patients for future studies
- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database
| Yes/No | % available | |
| Data summarised in database | yes | 95 |
| Database is web-based | no | |
| Database on spreadsheet | yes | |
| Database is on paper | yes | |
| Other (specify) |
Language used:
English
13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups
- Access through collaboration with PI only
15. Data sharing policy specified as a condition of use
- No requirement to make data publicly available
16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA
- Living donors:blood
- Living donors: DNA
- Living donors: cerebro-spinal fluid
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups
- Yes, for all the cohort